Related Experiment Video
Updated: Aug 14, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
Samuel Theodorus Sutanto1, Robert Sinto, Adeline Pasaribu
1Faculty of Medicine, Universitas Kristen Krida Wacana, Jakarta, Indonesia. samytheodorus23@gmail.com.
Abstract:
Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, molnupiravir and nirmatrelvir/ritonavir, that have been studied extensively in treating COVID-19 with promising results, and their availability in Indonesia. Molnupiravir and nirmatrelvir/ritonavir are two of many repurposed drugs in clinical trials, which have been reported to have a mechanism in quick clearance of SARS-CoV-2, reduction in viral load, and fast symptoms recovery time in phase 1 and 2 clinical trials. Phase 2/3 clinical study in COVID-19 patients without any indication for hospitalization showed that molnupiravir and nirmatrelvir/ritonavir significantly reduced the risk of hospitalization and death.
Related Concept Videos
Subviral Agents
Retroviruses
Retrovirus Life Cycles
Viruses with RNA Genomes

